Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 3 for:    CAR | cancer | New Zealand
Previous Study | Return to List | Next Study

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04049513
Recruitment Status : Recruiting
First Posted : August 8, 2019
Last Update Posted : February 20, 2020
Wellington Zhaotai Therapies Limited (WZTL)
Information provided by (Responsible Party):
Malaghan Institute of Medical Research

Brief Summary:
This Phase 1, single centre, open label dose escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-cells (WZTL-002) in the treatment of patients with relapsed or refractory (r/r) B-cell Non Hodgkin Lymphoma, for use in further efficacy trials.

Condition or disease Intervention/treatment Phase
Lymphomas Non-Hodgkin's B-Cell Diffuse Large B-cell Lymphoma (DLBCL) Primary Mediastinal B-cell Lymphoma (PMBCL) Transformed Follicular Lymphoma (TFL) Follicular Lymphoma (FL) Mantle Cell Lymphoma (MCL) Biological: WZTL002-1 (1928T2z CAR-T cells) Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy Phase 1

Detailed Description:

This is a Phase 1 dose escalation study, designed to evaluate the safety, feasibility, efficacy and kinetics of third-generation autologous anti-CD19 CAR T-cells, WZTL-002, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma without other curative options. A 3+3 dose escalation design will be used to identify a Maximum Tolerated Dose (MTD) of WZTL-002 using pre-defined Dose Limiting Toxicity (DLT) criteria.

Eligible participants will undergo leukapheresis to harvest peripheral blood mononuclear cells, the starting material for the manufacture of the autologous third generation anti-CD19 CAR T-cell product, WZTL-002. After WZTL-002 manufacture and confirmation that product release criteria are met, participants will receive lymphodepleting chemotherapy comprising fludarabine and cyclophosphamide on days -5 to day -3, inclusive. WZTL-002 will be administered intravenously on day 0 as a single dose.

Following WZTL-002 administration, participants will be monitored closely for 14 days, including targeted assessments for the specific CAR T-cell related toxicities of Cytokine Release Syndrome (CRS) and Immune Effector Cell Neurotoxicity Syndrome (ICANS). Initial DLT assessment will occur at day 21 after WZTL-002 infusion. A PET/CT Scan to assess treatment response will take place 3 months after WZTL-002 infusion, marking the end of the primary follow up period. The secondary follow up period will occur between 3 months up until 2 years after WZTL-002 treatment. Long term follow up within the trial will occur annually from 2 to 5 years after WZTL-002 treatment, with further follow-up within the Center for International Blood and Marrow Transplant Research (CIBMT) Cellular Therapies Registry and the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). In addition to clinical data, this study incorporates sample collection for exploratory endpoints including serum cytokine profile following WZTL-002 infusion, and WZTL-002 expansion, persistence and phenotype.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Sequential Assignment
Intervention Model Description: Modified 3+3 dose escalation scheme.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas
Actual Study Start Date : October 11, 2019
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : August 2026

Arm Intervention/treatment
Experimental: WZTL002-1 (1928T2z CAR T-cells)

A starting WZTL-002 dose of 5 × 10^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.

Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level.

Biological: WZTL002-1 (1928T2z CAR-T cells)
WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.

Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
Cyclophosphamide 500 mg/m^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m^2 IV on days -5 to -3, inclusive

Primary Outcome Measures :
  1. Number and severity of adverse events assessed by CTCAE v5.0, except for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome, which will be assessed by ASTCT consensus grading criteria [ Time Frame: 3 months after administration ]
    Determine the safety profile of WZTL-002, anti-CD19 CAR T-cells by measuring frequency and severity of adverse events

Secondary Outcome Measures :
  1. Feasibility of Manufacture [ Time Frame: 3 months after administration ]
    To investigate the feasibility of manufacture and treatment with WZTL-002, as determined by the proportion of enrolled participants undergoing at least one study leukapheresis procedure that receive WZTL-002

  2. Overall Response Rate [ Time Frame: 3 months after administration ]
    To estimate the overall response rate (ORR) as determined by complete response (CR) plus partial response (PR) 3 months after WZTL-002 administration

  3. Cumulative CR rate [ Time Frame: 6 months after administration ]
    To determine the cumulative CR rate 6 months after WZTL-002 administration

  4. Relapse-free survival [ Time Frame: 24 months after administration ]
    To estimate the relapse-free survival (RFS) for subjects treated with WZTL-002 over a period of 24 months after WZTL-002 administration

  5. Overall survival [ Time Frame: 24 months after administration ]
    To estimate the overall survival (OS) distribution for subjects treated with WZTL-002 over a period of 24 months after WZTL-002 administration

  6. Recommended dose [ Time Frame: 3 months after administration ]
    To determine the recommended phase 2 dose of WZTL-002 for treatment of R/R B-NHL

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 16 to 75 years (inclusive)
  • Biopsy-proven relapsed or treatment refractory aggressive B-cell non-Hodgkin lymphoma of the following subtypes per World Health Organisation (WHO) classification: DLBCL and its variants, PMBCL, tFL, FL, MCL
  • Requirement for treatment in the opinion of the investigator
  • No other curative treatments available, or not suitable due to patient or disease characteristics or lack of stem cell donor
  • Malignancy documented to express CD19 based on flow cytometric or immunohistochemical staining
  • Provision of written informed consent for this study
  • Life-expectancy from non-lymphoma related causes of > 12 months
  • European Cooperative Oncology Group (ECOG) performance status of 0 to 2 inclusive
  • Adequate haematologic function, defined by neutrophils ≥ 1.0 × 10^9/L and platelets ≥ 50 × 10^9/L
  • No serious cardiac, pulmonary, hepatic or renal disease.

    • Serum bilirubin < 2.5 times Upper limit of normal (ULN)
    • Estimated creatinine clearance (CrCl) ≥ 50 mL/min using the modified Cockroft Gault estimation or as assessed by direct measurement
    • Cardiac Ejection Fraction ≥ 50% as determined by Echocardiogram or MUGA Scan
    • Oxygen saturations > 92% on room air
    • Diffuse Capacity of the lungs for carbon monoxide (DLCO) or Carbon monoxide transfer coefficient (KCO), Forced expiratory volume in one second (FEV1) and Forced Vital Capacity (FVC) are all ≥ 50% of predicted by spirometry after correcting for haemoglobin and/or volume on lung function testing.

Exclusion Criteria:

  • Confirmed active or prior central nervous system (CNS) involvement by lymphoma. In patients with a clinical suspicion of CNS disease, lumbar puncture and MRI brain must be performed
  • Active CNS pathology including: epilepsy, seizure within the preceding year, aphasia, paresis, stroke, dementia, psychosis within the preceding year, severe brain injury, Parkinson disease, or cerebellar disease
  • Richter Syndrome
  • Active autoimmune disease requiring systemic immunosuppression
  • Prior solid organ transplantation
  • Allogeneic stem cell transplantation within the preceding three months or still requiring systemic immunosuppression
  • Current grade II - IV acute graft versus host disease (GVHD), any prior grade IV acute GVHD, or current moderate or severe chronic GVHD
  • Need for systemic corticosteroids to treat a condition other than B-NHL at a daily dose of ≥ 10 mg prednisone (or equivalent)
  • Peripheral blood lymphocytes < 0.5 x 10^9/L as assessed by complete blood count
  • Peripheral blood CD3+ T cells < 350/μL as assessed by lymphocyte subset analysis
  • Pregnant or lactating female
  • Women of child-bearing potential who are not willing to use highly effective methods of contraception during study participation and for at least 1 year after WZTL-002 administration
  • Men who are not willing to use highly effective methods of contraception during study participation and for at least 1 year after WZTL-002 administration
  • Men who have a pregnant partner and are not willing to use a condom while performing sexual activity during study participation and for at least 3 months after WZTL-002 administration
  • Participants with known sensitivity to immunoglobulin or to components of the investigational product (IP)
  • History of active malignancy other than B-cell malignancy within two years prior to enrolment, with the exception of: adequately treated in situ carcinoma of the cervix; adequately treated basal cell carcinoma (BCC) or localized squamous cell carcinoma (SCC) of the skin; other localised malignancy surgically resected (or radically treated with another treatment modality) with curative intent
  • Current or prior human immunodeficiency virus (HIV) infection
  • Vaccination with a live virus within the preceding four weeks
  • Treatment with a purine analogue within the preceding four weeks
  • Treatment with alemtuzumab within the preceding 12 weeks
  • Prior gene therapy, including prior anti-CD19 chimeric antigen receptor T-cell therapy
  • Receipt of an investigational medicine within another clinical trial within the preceding four weeks
  • Inadequately controlled systemic infection
  • Serologic status reflecting active viral hepatitis B or any history of hepatitis C infection as follows:

    • Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (< 20 IU), and if they are willing to receive appropriate anti-viral prophylaxis.
    • Presence of hepatitis C virus (HCV) antibody
  • Presence of New York Heart Association (NYHA) class 2 or higher cardiac symptoms not related to lymphoma
  • Significant concomitant illnesses which would in the investigator's opinion make the patient an unsuitable candidate for the trial
  • Participants who have diminished capacity or any circumstance that would prohibit them from understanding and providing informed consent in accordance with ICH-GCP (International Conference on Harmonisation, Good Clinical Practice)
  • Participant does not provide consent to enrol onto International Cellular Therapy Registry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04049513

Layout table for location contacts
Contact: Robert Weinkove, MBBS, PhD +64 4 918 5117
Contact: Tess Ostapowicz, BA +64 4 918 5117

Layout table for location information
New Zealand
Wellington Hospital, Capital & Coast District Health Board Recruiting
Wellington, New Zealand, 6021
Contact: Robert Weinkove, Dr.         
Contact: Philip George         
Principal Investigator: Robert Weinkove, MBBS, PhD         
Sub-Investigator: Philip E George, MBChB         
Sub-Investigator: Alwyn AB D'Souza, MBChB         
Sub-Investigator: Travis N Perera, MBChB         
Sponsors and Collaborators
Malaghan Institute of Medical Research
Wellington Zhaotai Therapies Limited (WZTL)
Layout table for investigator information
Principal Investigator: Robert Weinkove, MBBS, PhD Capital and Coast District Health board
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Malaghan Institute of Medical Research Identifier: NCT04049513    
Other Study ID Numbers: WZTL002-1
U1111-1216-2053 ( Other Identifier: World Health Organisation )
First Posted: August 8, 2019    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All IPD that underlie results in a publication

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Malaghan Institute of Medical Research:
Lymphomas Non-Hodgkin's B-Cell
Chimeric antigen receptor T-cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoma, Follicular
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists